Mutations in the RAS signaling pathway (red star) are frequently present in a small subset of leukemic blast cells at diagnosis of pediatric ALL. Cells harboring the mutation may survive chemotherapy, resulting in relapse, which could be treatable with selumetinib, targeting MEK downstream of RAS signaling. Professional illustration by Patrick Lane, ScEYEnce Studios.